The Development Center for Biotechnology (DCB), a research institute in Taiwan, said on Friday that six Taiwanese biomedical startups held more than 100 one-on-one business meetings with global pharmaceutical companies, investors, industry partners and research organisations at the BIO International Convention 2026 in San Diego, California, in June.

These meetings created new opportunities for strategic partnerships, technology commercialisation and international market expansion.

Supported by the National Development Council's (NDC) national startup brand, Startup Island TAIWAN, the delegation was led by DCB through the Taiwan–Berkeley Health Innovation Accelerator. It brought together six Taiwanese biomedical startups: AB DigiHealth Inc in AI-powered precision health, AcadeMab Biomedical Inc in next-generation antibody therapeutics, PlasmonicTron Co Ltd in biosensing technologies, Taiwan Universe BioMedicine Inc in vaccine development, CancerFree Biotech in organoid platforms, and Precisemab Biotech Co Ltd in precision medicine.

Together, the companies promoted Taiwan's strength in AI-powered precision health, oncology therapeutics, organoid platforms, vaccine development, precision medicine and next-generation antibody technologies at BIO 2026.

The companies reported strong interest from international pharmaceutical companies, investors, and industry partners across a range of biomedical fields.